Genetics in medicine : official journal of the American College of Medical Genetics · 2026
Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainment.
СтатьяResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Jung, Ney Gina, Frone Megan N, Haley Jeremy S, Ramos Mark Louis F, Mirshahi Uyenlinh L, Astiazaran-Symonds Esteban, Shandrina Mariya, Urban Gretchen, Rao H Shanker, Stahl Richard C, Golden Alicia, Yohe Marielle E, Gross Andrea M, Ding Yi, Carey David J, Gelb Bruce D, Stewart Douglas R
Аннотация
PURPOSE: Genomic ascertainment of electronic health record-linked exome data was used to quantify germline pathogenic/likely pathogenic variant prevalence, cancer prevalence, and survival in adults with non-NF1 RAS/mitogen-activated protein kinase genes (RASopathies).
METHODS: Germline RASopathy variants were examined from adult participants in UK Biobank (UKBB; n = 469,802), Geisinger MyCode (n = 167,050), and Mount Sinai BioMe (n = 30,470). Variants were classified as per American College of Medical Genetics/Association for Molecular Pathology criteria and reviewed by a RASopathy variant expert. Heterozygotes harbored a RASopathy pathogenic/likely pathogenic variant; non-heterozygotes harbored wild type or benign/likely benign RASopathy variation. To distinguish germline variants from clonal hematopoiesis, benign tissues were Sanger sequenced. Phenotype data were extracted.
RESULTS: Noonan syndrome-associated genes heterozygotes (excluding known Noonan syndrome with multiple lentigines variants) were most common with an estimated prevalence ranging between 1:1772 to 1:3330 in the cohorts. In SPRED1 (HGNC:20249) heterozygotes, cancer prevalence was only significantly increased in UKBB (OR: 3.8 [95% CI: 2.48-8.64]; P = 1.2 × 10-3). In MyCode and UKBB cohorts, no sufficient evidence of increased cancer risk was found in Noonan-, CBL- (HGNC:1541) and cardiofaciocutaneous syndrome heterozygotes.
CONCLUSION: In some RASopathies, adult cancer risk may not be elevated. These findings merit replication. There may be an increased cancer risk for adult SPRED1 heterozygotes.
METHODS: Germline RASopathy variants were examined from adult participants in UK Biobank (UKBB; n = 469,802), Geisinger MyCode (n = 167,050), and Mount Sinai BioMe (n = 30,470). Variants were classified as per American College of Medical Genetics/Association for Molecular Pathology criteria and reviewed by a RASopathy variant expert. Heterozygotes harbored a RASopathy pathogenic/likely pathogenic variant; non-heterozygotes harbored wild type or benign/likely benign RASopathy variation. To distinguish germline variants from clonal hematopoiesis, benign tissues were Sanger sequenced. Phenotype data were extracted.
RESULTS: Noonan syndrome-associated genes heterozygotes (excluding known Noonan syndrome with multiple lentigines variants) were most common with an estimated prevalence ranging between 1:1772 to 1:3330 in the cohorts. In SPRED1 (HGNC:20249) heterozygotes, cancer prevalence was only significantly increased in UKBB (OR: 3.8 [95% CI: 2.48-8.64]; P = 1.2 × 10-3). In MyCode and UKBB cohorts, no sufficient evidence of increased cancer risk was found in Noonan-, CBL- (HGNC:1541) and cardiofaciocutaneous syndrome heterozygotes.
CONCLUSION: In some RASopathies, adult cancer risk may not be elevated. These findings merit replication. There may be an increased cancer risk for adult SPRED1 heterozygotes.